RT Journal Article
T1 Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain.
A1 Ribera, Josep-Maria
A1 Morgades, Mireia
A1 Coll, Rosa
A1 Barba, Pere
A1 López-Lorenzo, Jose-Luis
A1 Montesinos, Pau
A1 Foncillas, María-Angeles
A1 Cabrero, Mónica
A1 Gómez-Centurión, Ignacio
A1 Morales, María-Dolores
A1 Varela, María-Rosario
A1 Herrera, Pilar
A1 García-Cadenas, Irene
A1 Calbacho, María
A1 Torrent, Anna
A1 Maluquer, Clara
A1 Calabuig, Marisa
A1 Garcia-Guiñon, Antoni
A1 Bautista, Guiomar
A1 Llorente, Laura
A1 Gil, Cristina
A1 Artola, María-Teresa
A1 González-Campos, José
A1 Fernández-Moreno, Ainhoa
A1 Bárez, Abelardo
A1 Giménez-Pérez, Teresa
A1 Bergua, Juan
A1 Sánchez-Sánchez, María-José
A1 Mateos, María-Carmen
A1 Piñana, José-Luis
K1 Acute lymphoblastic leukemia
K1 Adults
K1 Covid-19 infection
K1 Outcome
AB SARS-CoV-2 infection has bimodal distribution in Europe with a first wave in March to June 2020 and a second in September 2020 to February 2021. We compared the frequency, clinical characteristics and outcomes of adults with acute lymphoblastic leukemia (ALL) and infection in the first vs. second pandemic waves in Spain. In this prospective study the characteristics of ALL and COVID-19 infection, comorbidities, treatment and outcome in the two periods were compared. The study ended when vaccination against SARS-CoV-2 was implemented in Spain. Twenty eight patients were collected in the first wave and 24 in the second. The median age was 46.5 years (range 20-83). Patients from the first wave had a trend to more severe ALL (higher frequency of patients under induction or submitted to transplantation or under immunosuppressive therapy). No significant differences were observed in need for oxygen support, intensive care unit (ICU) requirement, days in ICU and time to COVID-19 infection recovery. Seventeen patients (33%) died, with death attributed to COVID infection in 15 (29%), without significant differences in the 100 day overall survival (OS) probabilities in the two waves (68% ± 17% vs. 56% ± 30%). The only prognostic factor for OS identified by was the presence of comorbidities at COVID-19 infection (HR: 5.358 [95% CI: 1.875- 15.313]). The frequency and mortality of COVID-19 infection were high in adults with ALL, without changes over time, providing evidence in favor of vaccination priority for these patients.
YR 2021
FD 2021-07-18
LK https://hdl.handle.net/10668/25347
UL https://hdl.handle.net/10668/25347
LA en
DS RISalud
RD Apr 17, 2025